Granulocyte and granulocyte macrophage colony-stimulating factors as therapy in human and veterinary medicine

Veterinary Journal

Volumn 174, Issue 1, 2007, Pages 33-41

  Fernández Varón, Emilio ^a   Villamayor, Lucía ^b  

^a UNIVERSITY OF MURCIA   (Spain)

^b Santa Maria del Rosell University Hospital   (Spain)

Author keywords

Chemotherapy; G CSF; GM CSF; Growth factors; Neutropenia; Oncology

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY; ZIDOVUDINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ASTHENIA; BACKACHE; BONE PAIN; CELL DIFFERENTIATION; CHILL; CLINICAL TRIAL; CONTINUOUS INFUSION; DIAPHORESIS; DIARRHEA; DOSE RESPONSE; DROWSINESS; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FLUSHING; GENE IDENTIFICATION; GRANULOPOIESIS; HUMAN; HYPOTENSION; INFECTION; INJECTION SITE REACTION; LETHARGY; LEUKOCYTOSIS; LUNG EDEMA; MALAISE; MOLECULAR CLONING; MORBIDITY; MORTALITY; MOUTH INFLAMMATION; MUSCLE SPASM; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIMARY PREVENTION; PROTEIN FUNCTION; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; RIGOR; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN MANIFESTATION; SPLEEN RUPTURE; SPLENOMEGALY; STEM CELL MOBILIZATION; TACHYCARDIA; THROMBOCYTOPENIA; VOMITING;

ANIMALS; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIESIS; HUMANS; NEUTROPENIA; VETERINARY MEDICINE;

EID: 34249937796     PISSN: 10900233     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tvjl.2006.08.001     Document Type: Review

References (69)

1. Antin J.H., Smith B.R., Holmes W., David R.N., and Rosenthal S. Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood 72 (1988) 705-713
2. Balaguer H., Galmes A., Ventayol G., Bargay J., and Besalduch J. Splenic rupture after granulocyte-colony-stimulating factor mobilization in a peripheral blood progenitor cell donor. Transfusion 44 (2004) 1260-1261
3. Bessho M., Hirashima K., Asano S., Ikeda Y., Ogawa N., Tomonaga M., Toyama K., Nakahata T., Nomura T., Mizoguchi H., Yoshida Y., Niitsy Y., and Kohgo Y. Treatment of the anemia of aplastic anemia patients with recombinant human erythropoietic in combination with granulocyte colony-stimulating factor: a multicenter randomized controlled study. European Journal of Haematology 8 (1997) 265-272
4. Bishop M.R., Anderson J.R., Jackson J.D., Bierman P.J., Reed E.C., Vose J.M., Armitage J.O., Warkentin P.I., and Kessinger A. High-dose therapy and peripheral blood progenitor cell transplantation: effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft. Blood 83 (1994) 610-616
5. Blaise D., Kuentz M., Fortanier C., Bourhis J.H., Milpred N., Sutton L., Jovet J.P., Attal M., Bordigoni P., Cahn J.Y., Boiron J.M., Schuller M.P., Moatti J.P., and Michallet M. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia. Journal of Clinical Oncology 18 (2000) 537-546
6. Cebon J.S., Dempsey P., Fox R., Kannourakis G., Bonnem E., Burgess A.W., and Morstyn G. Pharmacokinetics of human granulocyte-macrophage colony-stimulating factor using a sensitive immunoassay. Blood 72 (1988) 1340-1347
7. Cebon J.S., Bury R.W., Lieschke G.J., and Morstyn G. The effects of dose and route of administration on the pharmacokinetics of granulocyte-macrophage colony-stimulating factor. European Journal of Cancer 26 (1990) 1064-1069
8. Cebon J., Layton J.E., Maher D., et al. Endogenous hematopoietic growth factors in neutropenia and infection. British Journal of Haematology 86 (1994) 265-274
9. Chatta G.S., Price T.H., Allen R.C., and Dale D.C. Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming units in healthy young and elderly adult volunteers. Blood 84 (1994) 2923-2929
10. Cheers C., Haigh A.M., Kelso A., Metcalf D., Stanley E.R., and Young A.M. Production of colony-stimulating factors (CSFs) during infection: separate determinations of macrophage-, granulocyte-macrophage-, and multi-CSFs. Infectious Immunology 56 (1988) 247-251
11. Chevallier B., Chollet P., Merrouche Y., Roche H., Fumolean P., Kerbrat P., Genot J.Y., Fargeot P., Olivier J.P., and Fizarnes C. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. Journal of Clinical Oncology 13 (1995) 1564-1571
12. Clark, O.A., Lyman, G., Castro, A.A., Clark, L.G., Djulbegovic, B., 2003. Colony stimulating for chemotherapy induced febrile neutropenia. Cochrane Database System Review, CD003039.
13. Crawford J. Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia. Drugs 62 Suppl. 1 (2002) 89-98
14. Dale D.C. The discovery, development and clinical applications of granulocyte colony-stimulating factor. Transactions of the American Clinical and Climatological Association 92 (1998) 2629-2640
15. Dale D.C. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 62 Suppl. 1 (2002) 1-15
16. Dale D.C., Bonilla M.A., Davis M.W., Nakanishi A.M., Hammond W.P., Hurtzberg J., Wang W., Jakubowski A., Winton E., and Lalezari P. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 81 (1993) 2496-2502
17. Donadieu J., Bader-Meunier B., Bertrand Y., Lachaux A., Labrune P., Gougerot-Pocigalo M.A., Odievre M., Gibeaud P., Yver A., and Tchernia G. Recombinant human G-CSF (lenograstim) for infectious complications in glycogen storage disease type Ib. Nouvelle Revue Française D'Hematologie 35 (1993) 529-534
18. Dort R.T. Clinical properties of yeast-derived versus Escherichia coli-derived granulocyte-macrophage colony-stimulating factor. Clinical Therapeutics 15 (1993) 19-29
19. Dunham S.P. Cytokines and anti-cytokine therapy: clinical potential for treatment of feline disease. Journal of Feline Medicine and Surgery 1 (1999) 7-14
20. Durhsen U., Villeral J.L., Boyd J., Kannourakis G., Morstyn G., and Metcalf D. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 72 (1988) 2074-2081
21. Eguchi K., Sasaki S., Tamura T., Sasaki Y., Shinkai T., Yamada K., Soejima Y., Fukuda M., Fujihara Y., and Kunitou H. Dose escalation study of recombinant human granulocyte colony-stimulating factor (KRN8601) in patients with advanced malignancy. Cancer Research 49 (1989) 5221-5224
22. Fulton R., Gasper P.W., Ogilvie G.K., Boone T.C., and Dornsife R.E. Effect of recombinant human granulocyte colony-stimulating factor on hemopoiesis in normal cats. Experimental Hematology 19 (1993) 759-767
23. Geissler K., Koller E., Hubmann E., Niederwieser D., Hinterberger W., Geissler D., Kyrle P., Knobl P., Pabinger I., Thalhammer R., Schwarzinger I., Mannhalter C., Jaeger U., Heinz R., Linkesh W., and Lechner K. Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia - a randomized phase III study. Blood 90 (1997) 590-596
24. Gisselbrecht C., Prentice H.G., Bacigalupo A., Biron P., Milpied N., Rubie N., Cunningham D., Legros M., Pico J.L., and Linch D.C. Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation. Lancet 343 (1994) 696-700
25. Gluckman E., Rokicka-Milewska R., Hann I., Nikiforakis E., Tavakoli F., Cohen-Scali S., and Bacigalupo A. Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. British Journal of Haematology 119 (2002) 1075-1082
26. Goodman S.A., Brewer W.G., Henry C.J., McPhearson C.J., Murray S., Abraha T., and Lothrop Jr. C.D. Antibody formation to rhG-CSF is delayed in dogs treated with chemotherapeutic drugs (Abstract). Journal of Veterinary Internal Medicine 4 (1990) 111
27. Heath J.A., Steinherz P.G., Altman A., Sather H., Jhanwar S., Halpem S., Pieters R., Shah N., Steinherz L., Tannous R., Terry W., Trigg M.E., and Children's Cancer Group. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Journal of Clinical Oncology 21 (2003) 1612-1617
28. Heuser M., and Ganser A. Colony-stimulating factors in the management of neutropenia and its complications. Annals of Hematology 84 (2005) 697-708
29. Holmes, F.A., Jones, S.E., O'Shaughnessy, J., 2000. A single dose of pegfilgrastim is as effective as daily filgrastim to reduce the duration of severe, chemotherapy-induced neutropenia. In: Proceedings of the 36th ASCO Annual Meeting.
30. Johnston E., Crawford J., Blackwell S., Bjurstrom T., Lockbaum P., Roskos L., Yang B.B., Gardner S., Miller-Messana M.A., Shoemaker D., Garst J., and Schwab G. Randomized, dose-scalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. Journal of Clinical Oncology 18 (2000) 2522-2528
31. Kaito K., Kobayashi M., Katayama T., Masuoka H., Shimada T., Nishiwaki K., Sekita T., Otsubo H., Ogasawara Y., and Hosoya T. Long-term administration of G-CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults. British Journal of Haematology 103 (1998) 297-303
32. Kojima S., Ohara A., Tsuchida M., Kudoh T., Hanada R., Okimoto Y., Kaneko T., Takano T., Ikuta k., and Tsukimoto I. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood 100 (2002) 786-790
33. Kuffer-Frank, M., Kraft, W., 1998. Use of recombinant human granulocyte colony stimulating factor (r-met-hu-G-CSF) in neutropenic cats (Abstract). In: 41st British Small Animal Veterinary Association congress paper synopses 276.
34. Kumar M., and Alter B.P. Hematopoietic growth factors for the treatment of aplastic anemia. Current Opinion in Hematology 5 (1998) 226-234
35. Kuritzkes D.R. Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor. Clinical Infectious Diseases 30 (2000) 256-260
36. Lanevschi A., Daminet S., Niemeyer G.P., and Lothrop Jr. C.D. Granulocyte colony-stimulating factor deficiency in a Rottweiler with chronic idiopathic neutropenia. Journal of Veterinary Internal Medicine 13 (1999) 72-75
37. Larson R.A., Dodge R.K., Linker C.A., Stone R.M., Powell B.L., Lee E.J., Scgulman P., Davey F.R., Frankel S.R., Bloomfield C.D., George S.L., and Schiffer C.A. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia, CALGB study 9111. Blood 92 (1998) 1556-1564
38. Lieschke G.J., Cebon J., and Morstyn G. Characterization of the clinical effects after the first dose of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor. Blood 74 (1989) 2634-2643
39. Lieschke G.J., Maher D., O'Connor M., Green M., Sheridan W., Rallings M., Bonnem E., Burgess A.W., McGrath K., and Fox R.M. Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration. Cancer Research 50 (1990) 606-614
40. Linch D.C., Scarffe H., Proctor S., Chopra R., Taylor P.R., Morgentern G., Cunningham D., Burnett A.K., Cawley J.C., and Franklin I.M. Randomized vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. Bone Marrow Transplant 11 (1993) 307-311
41. Logothetis C.J., Dexeus F.H., Sella A., Amato R.J., Kilbourn R.G., Finn L., and Gutterman J.U. Escalated therapy for refractory urothelial tumours: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor. Journal of National Cancer Institute 82 (1990) 667-672
42. Metcalf D. The colony-stimulating factors: discovery, development, and clinical applications. Cancer 65 (1990) 2185-2195
43. Metcalf D. Hematopoietic regulators: redundancy or subtlety. Blood 82 (1993) 3515-3523
44. Meyer D.J., and Harvey J.W. Veterinary laboratory medicine: interpretation and diagnosis. second ed. (1998), W.S. Saunders Company, Philadelphia
45. Micromedex Data Base, 2006.
46. Milkovich G., Moleski R.J., Reitan J.F., Dunning D.M., Gibson G.A., Paivanas T.A., Wyant S., and Jacobs R.J. Comparative safety of filgrastim versus sargramostim in patients receiving myelosuppressive chemotherapy. Pharmacotherapy 20 (2000) 1432-1440
47. Mischke R., Barth T., Wohlsein P., Rohn K., and Nolte I. Effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on leukocyte count and survival rate of dogs with parvoviral enteritis. Research in Veterinary Science 70 (2001) 221-224
48. Molineux G., Kinstler O., Briddell B., Hartley C., McElroy P., Kerzic P., Sutherland W., Stoney G., Kern B., Fletcher F.A., Cohen A., Korach E., Ulich T., McNiece I., Lockbaum P., Miller-Messana M.A., Gardner S., Hunt T., and Schwab G. A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Experimental Hematology 27 (1999) 1724-1734
49. Morstyn G., Lieschke G.J., and Sheridan W. Pharmacology of the colony-stimulating factors. Trends in Pharmacological Sciences 10 (1989) 154-159
50. Obradovich J.E., Ogilvie G.K., Stadler-Morris S., Schmidt B.R., Cooper M.F., and Boone T.C. Effect of recombinant canine granulocyte colony-stimulating factor on peripheral blood neutrophil counts in normal cats. Journal of Veterinary Internal Medicine 7 (1993) 65-67
51. Ozer H., Armitage J.O., Bennett C.L., Crawford J., Demetri G.D., Pizzo P.A., Schiffer C.A., Smith T.J., Somlo G., Wade J.C., Wade III J.L., Winn R.J., Wozniak A.J., and Somerfield M.R. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. Journal of Clinical Oncology 18 (2000) 3558-3585
52. Pagliuca A., Carrington P.A., Pettengell R., Tule S., and Keidan J. Guidelines on the use of colony-stimulating factors in haematological malignancies. British Journal of Haematology 123 (2003) 22-23
53. Platzbecker U., Prange-Krex G., Bornhauser M., Koch R., Soucek S., Aikele P., Haack A., Haag C., Schiler U., Berndt A., Rutt C., Ehninger G., and Holig K. Spleen enlargement in healthy donors during G-CSF mobilization of PBPCs. Transfusion 41 (2001) 184-189
54. Rewerts J.M., McCaw D.L., Cohn L.A., Wagner-Mann C., and Harrington D. Journal of American Veterinary Medicine Association 15 213 (1998) 1698
55. Rini B., Wadhwa M., Bird C., Small E., Gaines-Das R., and Thorpe R. Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF). Cytokine 29 (2005) 56-66
56. Roberts A.W. G-CSF: a key regulator of neutrophil production, but that's not all. Growth Factors 23 (2005) 33-41
57. Roskos L.K., Yang B., and Schwab G. A cytokinetic model describes the granulopoietic effects of r-metHuG-CSF-SD/01 (SD/01) and the homeostatic regulation of SD/01 clearance in normal volunteers. Clinical Pharmacology and Therapeutics 65 (1999) 196
58. Schleuning M., Thoedtmann R., Josten K., Baurmann H., and Schwerdtfeger R. The impact of post transplant use of G-CSF on event free survival in AML patients undergoing allogenic stem cell transplantation from unrelated donors and in vivo T-cell depletion with ATG. Proceedings of the 22nd ASCO Annual Meeting, Abstract 6637. Journal of Clinical Oncology (2005)
59. Schmitz N., Linch D.C., Dreger P., Goldstore A.H., Boogaerts M.A., Ferrant A., Demuynck H.M., Link H., Zander A., and Barge A. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 347 (1996) 353-357
60. Steis R.G., VanderMolen L.A., Longo D.L., Clark J.W., Smith II J.W., Kopp W.C., Ruscetti F.W., Creekmore S.P., Elwood L.J., and Hursey J. Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase 1b trial. Journal of National Cancer Institute 82 (1990) 697-703
61. Stute N., Furman W.L., Schell M., and Evans W.E. Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in children after intravenous and subcutaneous administration. Journal of Pharmaceutical Sciences 84 (1995) 824-828
62. Tanaka H., Ishikawa K., Nishino M., Shimazu T., and Yoshioka T. Changes in granulocyte colony-stimulating factor concentration in patients with trauma and sepsis. Journal of Trauma-Injury Infection and Critical Care 40 (1996) 718-725
63. Thompson J.A., Lee D.J., Kidd P., Rubin E., Kaufmann J., Bonnem E.M., and Fefer A. Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects. Journal of Clinical Oncology 7 (1989) 629-637
64. Watts M.J., Addison I., Long S.G., Hartley S., Warrington S., Bayce M., and Linch D.C. Crossover study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated G-CSF in healthy volunteers. British Journal of Haematology 98 (1997) 474-479
65. Weiss D.J. Leukocyte disorders and their treatment. In: Kirk R.W. (Ed). Current Veterinary Therapy XII (1995), WB Saunders Co., Philadelphia p. 452
66. Yanay O., Brzezinski M., Christensen J., Liggitt D., Dale D.C., and Osborne W.R.A. An adult dog with cyclic neutropenia treated by lentivirus-mediated delivery of granulocyte colony-stimulating factor. Human Gene Therapy 17 (2006) 464-469
67. Yang, B.B., Lum, P., Renwick, J., 2000. Pharmacokinetic rationale for a fixed-dose regimen of a sustained-duration form of filgrastim in cancer patients. In: Proceedings of 42nd American Society of Hematology Meeting, San Francisco, USA, p. 157.
68. Yee G.C. Focus on GM-CSF and G-CSF: promising biotherapeutics for use in hematology and oncology. Hospital Formulary 25 (1990) 943-948
69. Zinkl J.G., Madigan J.E., Fridmann D.M., Kabbur M.B., Reynal-O'Connor J., and Andresen J.W. Haematological, bone marrow and clinical chemical changes in neonatal foals given canine recombinant granulocyte-colony stimulating factor. Equine Veterinary Journal 26 (1994) 313-318